BACKGROUND: Leptin replacement in patients with leptin gene mutations improves hypogonadotropic hypogonadism. The effects of leptin replacement on luteinizing hormone (LH) secretion in patients with lipodystrophy are unknown. AIM: We examined nocturnal LH secretory dynamics on and off exogenous leptin therapy using a 2-period, nonrandomized study that included leptin-naïve and leptin-treated subjects with lipodystrophy. METHODS: In period 1 (5 days) the leptin-treated group (n = 4) continued leptin; leptin was then withdrawn for the next 14 days (period 2). Leptin-naïve subjects (n = 8) were studied without leptin in period 1 and with leptin replacement in period 2. LH secretory dynamics were assessed (23:00-07:00 h, sampling every 10 min, analyzed by multiparameter deconvolution algorithm) at the end of each period. RESULTS: Mean (on vs. off: 5.0 ± 3.1 vs. 3.2 ± 1.3 IU/l, p = 0.04) and integrated LH concentrations (2,403 ± 1,495 vs. 1,534 ± 642 IU × l-1 × min-1, p = 0.04) were higher on leptin therapy. Leptin treatment increased burst mass (9.7± 15.4 vs. 7.0 ± 11.2 IU/l, p = 0.03) and tended to nonsignificantly increase LH burst frequency (0.77 ± 0.26 vs. 0.67 ± 0.24 h-1, p = 0.08). Consequently, leptin therapy increased the pulsatile production rate (64 ± 101 vs. 57 ± 73 IU × l-1 × 8 h-1, p = 0.01). On leptin, testosterone (507 ± 286 vs. 360 ± 174 ng/dl, p = 0.09) and estradiol levels (74 ± 36 vs. 29 ± 24 pg/ml, p = 0.01) were higher in males and females, respectively. CONCLUSIONS: Leptin increases spontaneous nocturnal LH secretion in patients with lipodystrophy. This is consistent with rodent and in vitro studies showing a direct stimulatory effect (hypothalamic, pituitary or both) of leptin on LH secretion. These novel findings may explicate some of the salutary effects of leptin therapy on the hypothalamic-pituitary-gonadal axis in lipodystrophy.
BACKGROUND:Leptin replacement in patients with leptin gene mutations improves hypogonadotropic hypogonadism. The effects of leptin replacement on luteinizing hormone (LH) secretion in patients with lipodystrophy are unknown. AIM: We examined nocturnal LH secretory dynamics on and off exogenous leptin therapy using a 2-period, nonrandomized study that included leptin-naïve and leptin-treated subjects with lipodystrophy. METHODS: In period 1 (5 days) the leptin-treated group (n = 4) continued leptin; leptin was then withdrawn for the next 14 days (period 2). Leptin-naïve subjects (n = 8) were studied without leptin in period 1 and with leptin replacement in period 2. LH secretory dynamics were assessed (23:00-07:00 h, sampling every 10 min, analyzed by multiparameter deconvolution algorithm) at the end of each period. RESULTS: Mean (on vs. off: 5.0 ± 3.1 vs. 3.2 ± 1.3 IU/l, p = 0.04) and integrated LH concentrations (2,403 ± 1,495 vs. 1,534 ± 642 IU × l-1 × min-1, p = 0.04) were higher on leptin therapy. Leptin treatment increased burst mass (9.7± 15.4 vs. 7.0 ± 11.2 IU/l, p = 0.03) and tended to nonsignificantly increase LH burst frequency (0.77 ± 0.26 vs. 0.67 ± 0.24 h-1, p = 0.08). Consequently, leptin therapy increased the pulsatile production rate (64 ± 101 vs. 57 ± 73 IU × l-1 × 8 h-1, p = 0.01). On leptin, testosterone (507 ± 286 vs. 360 ± 174 ng/dl, p = 0.09) and estradiol levels (74 ± 36 vs. 29 ± 24 pg/ml, p = 0.01) were higher in males and females, respectively. CONCLUSIONS:Leptin increases spontaneous nocturnal LH secretion in patients with lipodystrophy. This is consistent with rodent and in vitro studies showing a direct stimulatory effect (hypothalamic, pituitary or both) of leptin on LH secretion. These novel findings may explicate some of the salutary effects of leptin therapy on the hypothalamic-pituitary-gonadal axis in lipodystrophy.
Authors: I S Farooqi; S A Jebb; G Langmack; E Lawrence; C H Cheetham; A M Prentice; I A Hughes; M A McCamish; S O'Rahilly Journal: N Engl J Med Date: 1999-09-16 Impact factor: 91.245
Authors: C T Montague; I S Farooqi; J P Whitehead; M A Soos; H Rau; N J Wareham; C P Sewter; J E Digby; S N Mohammed; J A Hurst; C H Cheetham; A R Earley; A H Barnett; J B Prins; S O'Rahilly Journal: Nature Date: 1997-06-26 Impact factor: 49.962
Authors: J von Schnurbein; A Moss; S A Nagel; H Muehleder; K M Debatin; I S Farooqi; M Wabitsch Journal: Horm Res Paediatr Date: 2012-02-14 Impact factor: 2.852
Authors: Julio Licinio; Sinan Caglayan; Metin Ozata; Bulent O Yildiz; Patricia B de Miranda; Fiona O'Kirwan; Robert Whitby; Liyin Liang; Pinchas Cohen; Shalender Bhasin; Ronald M Krauss; Johannes D Veldhuis; Anthony J Wagner; Alex M DePaoli; Samuel M McCann; Ma-Li Wong Journal: Proc Natl Acad Sci U S A Date: 2004-03-09 Impact factor: 11.205
Authors: Jean L Chan; Kathleen Heist; Alex M DePaoli; Johannes D Veldhuis; Christos S Mantzoros Journal: J Clin Invest Date: 2003-05 Impact factor: 14.808
Authors: Rebecca M Fenichel; Jennifer E Dominguez; Laurel Mayer; B Timothy Walsh; Carol Boozer; Michelle P Warren Journal: Fertil Steril Date: 2008-03-04 Impact factor: 7.329
Authors: K Clément; C Vaisse; N Lahlou; S Cabrol; V Pelloux; D Cassuto; M Gourmelen; C Dina; J Chambaz; J M Lacorte; A Basdevant; P Bougnères; Y Lebouc; P Froguel; B Guy-Grand Journal: Nature Date: 1998-03-26 Impact factor: 49.962
Authors: Rebecca J Brown; Areli Valencia; Megan Startzell; Elaine Cochran; Peter J Walter; H Martin Garraffo; Hongyi Cai; Ahmed M Gharib; Ronald Ouwerkerk; Amber B Courville; Shanna Bernstein; Robert J Brychta; Kong Y Chen; Mary Walter; Sungyoung Auh; Phillip Gorden Journal: J Clin Invest Date: 2018-07-16 Impact factor: 14.808